Edwards Lifesciences Corp — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-06-09

Reporting Person: MUSSALLEM MICHAEL A (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-09	Common Stock	M	45050.0000	$21.7600	Acquired	233051.8200	Direct
2021-06-09	Common Stock	G	12500.0000	$0.0000	Disposed	220551.8200	Direct
2021-06-09	Common Stock	S	32550.0000	$97.2300	Disposed	188001.8200	Direct
2021-06-09	Common Stock	G	12500.0000	$0.0000	Acquired	3160287.0000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-09	Employee Stock Option (Right to Acquire)	$21.7600	M	45050.0000	Disposed	2022-05-13	Common Stock (45050.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	371728.8872	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $96.8350 to $97.7900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.